Francesco Atzori

5PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.

Alessandra Damassi, Malvina Cremante, Alessio Signori

|Apr 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.

Luca Cantini, Francesco Paoloni, Federica Pecci

|May 28, 2022
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study.

Matteo Brunelli, Guido Martignoni, Giorgio Malpeli

|May 14, 2022
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.

Umberto Basso, Federico Paolieri, Mimma Rizzo

|Jan 21, 2021
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.

A Mennitto, E Verzoni, F Cognetti

Pageof 1

Frequent Collaborators

3 joint publications

Sara Elena Rebuzzi

3 joint publications

Giuseppe Fornarini

2 joint publications

Pasquale Rescigno

2 joint publications

Alessio Signori